CONTEXT: Activation of the melanocortin-4 receptor (MC4R) with the synthetic agonist RM-493 decreases body weight and increases energy expenditure (EE) in nonhuman primates. The effects of MC4R agonists on EE in humans have not been examined to date. OBJECTIVE, DESIGN, AND SETTING: In a randomized, double-blind, placebo-controlled, crossover study, we examined the effects of the MC4R agonist RM-493 on resting energy expenditure (REE) in obese subjects in an inpatient setting. STUDY PARTICIPANTS AND METHODS: Twelve healthy adults (6 men and 6 women) with body mass index of 35.7 ± 2.9 kg/m(2) (mean ± SD) received RM-493 (1 mg/24 h) or placebo by continuous subcutaneous infusion over 72 hours, followed immediately by crossover to the alternate treatment. All subjects received a weight-maintenance diet (50% carbohydrate, 30% fat, and 20% protein) and performed 30 minutes of standardized exercise daily. Continuous EE was measured on the third treatment day in a room calorimeter, and REE in the fasting state was defined as the mean of 2 30-minute resting periods. RESULTS:RM-493 increased REE vs placebo by 6.4% (95% confidence interval, 0.68-13.02%), on average by 111 kcal/24 h (95% confidence interval, 15-207 kcal, P = .03). Total daily EE trended higher, whereas the thermic effect of a test meal and exercise EE did not differ significantly. The 23-hour nonexercise respiratory quotient was lower during RM-493 treatment (0.833 ± 0.021 vs 0.848 ± 0.022, P = .02). No adverse effect on heart rate or blood pressure was observed. CONCLUSIONS: Short-term administration of the MC4R agonist RM-493 increases REE and shifts substrate oxidation to fat in obese individuals.
RCT Entities:
CONTEXT: Activation of the melanocortin-4 receptor (MC4R) with the synthetic agonist RM-493 decreases body weight and increases energy expenditure (EE) in nonhuman primates. The effects of MC4R agonists on EE in humans have not been examined to date. OBJECTIVE, DESIGN, AND SETTING: In a randomized, double-blind, placebo-controlled, crossover study, we examined the effects of the MC4R agonist RM-493 on resting energy expenditure (REE) in obese subjects in an inpatient setting. STUDY PARTICIPANTS AND METHODS: Twelve healthy adults (6 men and 6 women) with body mass index of 35.7 ± 2.9 kg/m(2) (mean ± SD) received RM-493 (1 mg/24 h) or placebo by continuous subcutaneous infusion over 72 hours, followed immediately by crossover to the alternate treatment. All subjects received a weight-maintenance diet (50% carbohydrate, 30% fat, and 20% protein) and performed 30 minutes of standardized exercise daily. Continuous EE was measured on the third treatment day in a room calorimeter, and REE in the fasting state was defined as the mean of 2 30-minute resting periods. RESULTS: RM-493 increased REE vs placebo by 6.4% (95% confidence interval, 0.68-13.02%), on average by 111 kcal/24 h (95% confidence interval, 15-207 kcal, P = .03). Total daily EE trended higher, whereas the thermic effect of a test meal and exercise EE did not differ significantly. The 23-hour nonexercise respiratory quotient was lower during RM-493 treatment (0.833 ± 0.021 vs 0.848 ± 0.022, P = .02). No adverse effect on heart rate or blood pressure was observed. CONCLUSIONS: Short-term administration of the MC4R agonist RM-493 increases REE and shifts substrate oxidation to fat in obese individuals.
Authors: M Harris; C Aschkenasi; C F Elias; A Chandrankunnel; E A Nillni; C Bjøorbaek; J K Elmquist; J S Flier; A N Hollenberg Journal: J Clin Invest Date: 2001-01 Impact factor: 14.808
Authors: Jerry R Greenfield; Jeffrey W Miller; Julia M Keogh; Elana Henning; Julie H Satterwhite; Gregory S Cameron; Beatrice Astruc; John P Mayer; Soren Brage; Teik Choon See; David J Lomas; Stephen O'Rahilly; I Sadaf Farooqi Journal: N Engl J Med Date: 2008-12-17 Impact factor: 91.245
Authors: Paul Kievit; Heather Halem; Daniel L Marks; Jesse Z Dong; Maria M Glavas; Puspha Sinnayah; Lindsay Pranger; Michael A Cowley; Kevin L Grove; Michael D Culler Journal: Diabetes Date: 2012-10-09 Impact factor: 9.461
Authors: Jane E Royalty; Gitte Konradsen; Ole Eskerod; Birgitte S Wulff; Birgit S Hansen Journal: J Clin Pharmacol Date: 2013-11-19 Impact factor: 3.126
Authors: Jing Yu; Luis E Gimenez; Ciria C Hernandez; Yiran Wu; Ariel H Wein; Gye Won Han; Kyle McClary; Sanraj R Mittal; Kylie Burdsall; Benjamin Stauch; Lijie Wu; Sophia N Stevens; Alys Peisley; Savannah Y Williams; Valerie Chen; Glenn L Millhauser; Suwen Zhao; Roger D Cone; Raymond C Stevens Journal: Science Date: 2020-04-24 Impact factor: 47.728
Authors: Erica J P Anderson; Masoud Ghamari-Langroudi; Isin Cakir; Michael J Litt; Valerie Chen; Roman E Reggiardo; Glenn L Millhauser; Roger D Cone Journal: J Neuroendocrinol Date: 2019-01-20 Impact factor: 3.627
Authors: Robert J Brychta; Shan Huang; Juan Wang; Brooks P Leitner; Jacob D Hattenbach; Sarah L Bell; Laura A Fletcher; Rachel Perron Wood; Christopher R Idelson; Courtney J Duckworth; Suzanne McGehee; Amber B Courville; Shanna B Bernstein; Marc L Reitman; Aaron M Cypess; Kong Y Chen Journal: J Clin Endocrinol Metab Date: 2019-10-01 Impact factor: 5.958
Authors: Claudia K Fox; Amy C Gross; Eric M Bomberg; Justin R Ryder; Megan M Oberle; Carolyn T Bramante; Aaron S Kelly Journal: Curr Obes Rep Date: 2019-09